GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cantel Medical Corp (NYSE:CMD) » Definitions » ROE %

Cantel Medical (Cantel Medical) ROE % : 10.53% (As of Apr. 2021)


View and export this data going back to 1992. Start your Free Trial

What is Cantel Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Cantel Medical's annualized net income for the quarter that ended in Apr. 2021 was $84 Mil. Cantel Medical's average Total Stockholders Equity over the quarter that ended in Apr. 2021 was $802 Mil. Therefore, Cantel Medical's annualized ROE % for the quarter that ended in Apr. 2021 was 10.53%.

The historical rank and industry rank for Cantel Medical's ROE % or its related term are showing as below:

CMD' s ROE % Range Over the Past 10 Years
Min: 1.95   Med: 12.72   Max: 15.92
Current: 6.71

During the past 13 years, Cantel Medical's highest ROE % was 15.92%. The lowest was 1.95%. And the median was 12.72%.

CMD's ROE % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.31 vs CMD: 6.71

Cantel Medical ROE % Historical Data

The historical data trend for Cantel Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantel Medical ROE % Chart

Cantel Medical Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.93 14.59 16.07 8.67 1.97

Cantel Medical Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.95 -3.15 13.15 6.24 10.53

Competitive Comparison of Cantel Medical's ROE %

For the Medical Instruments & Supplies subindustry, Cantel Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantel Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cantel Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Cantel Medical's ROE % falls into.



Cantel Medical ROE % Calculation

Cantel Medical's annualized ROE % for the fiscal year that ended in Jul. 2020 is calculated as

ROE %=Net Income (A: Jul. 2020 )/( (Total Stockholders Equity (A: Jul. 2019 )+Total Stockholders Equity (A: Jul. 2020 ))/ count )
=13.708/( (661.537+729.599)/ 2 )
=13.708/695.568
=1.97 %

Cantel Medical's annualized ROE % for the quarter that ended in Apr. 2021 is calculated as

ROE %=Net Income (Q: Apr. 2021 )/( (Total Stockholders Equity (Q: Jan. 2021 )+Total Stockholders Equity (Q: Apr. 2021 ))/ count )
=84.472/( (787.666+817.19)/ 2 )
=84.472/802.428
=10.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Apr. 2021) net income data. ROE % is displayed in the 30-year financial page.


Cantel Medical  (NYSE:CMD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Apr. 2021 )
=Net Income/Total Stockholders Equity
=84.472/802.428
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(84.472 / 1255.812)*(1255.812 / 2040.794)*(2040.794 / 802.428)
=Net Margin %*Asset Turnover*Equity Multiplier
=6.73 %*0.6154*2.5433
=ROA %*Equity Multiplier
=4.14 %*2.5433
=10.53 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Apr. 2021 )
=Net Income/Total Stockholders Equity
=84.472/802.428
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (84.472 / 122.716) * (122.716 / 182.096) * (182.096 / 1255.812) * (1255.812 / 2040.794) * (2040.794 / 802.428)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6884 * 0.6739 * 14.5 % * 0.6154 * 2.5433
=10.53 %

Note: The net income data used here is four times the quarterly (Apr. 2021) net income data. The Revenue data used here is four times the quarterly (Apr. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Cantel Medical ROE % Related Terms

Thank you for viewing the detailed overview of Cantel Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantel Medical (Cantel Medical) Business Description

Traded in Other Exchanges
N/A
Address
150 Clove Road, 9th Floor, Little Falls, NJ, USA, 07424
Cantel Medical is a New Jersey-based manufacturer of hospital supplies for infection prevention, which include products used in endoscope disinfection, water purification systems for use in dialysis treatment, and dental supplies. The firm reports in four segments: medical (46% of fiscal 2020 sales), dental (32%), life sciences (19%), and dialysis (3%). Geographic exposure is primarily in the U.S., which accounts for about 75% of revenue, with international markets making up the remaining 25%.
Executives
Ann E Berman director 255 STATE STREET, BOSTON MA 02109
Jeffrey Z Mann officer: SVP, General Counsel 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
George L Fotiades director, officer: Chief Executive Officer 281 SUMMIT AVENUE, SUMMIT NJ 07901
Charles M Diker director, 10 percent owner, officer: Chairman ONE NEW YORK PLAZA, NEW YORK NY 10004
Shaun M. Blakeman officer: SVP - CFO C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Jean Casner officer: SVP and CHRO 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Brian Capone officer: SVP and Princ. Accounting Ofr 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Peter G Clifford officer: President and COO 40 TOURNAMENT DRIVE SOUTH, HAWTHORN WOODS IL 60047
Seth M Yellin officer: Executive Vice President 150 CLOVE ROAD 9TH FLOOR LITTLE FALLS NJ 07424
Laura L Forese director 849 STONEWALL COURT FRANKLIN LAKES NJ 07417
Peter Pronovost director JHU-QSRG 1909 THAMES ST. - 2ND FLOOR BALTIMORE MD 21231
Anthony B Evnin director C/O VENROCK ASSOCIATES, 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Ronnie Myers director TOURO COLLEGE OF DENTAL MEDICINE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595
Alan R Batkin director 399 PARK AVENUE, 10TH FLOOR, NEW YORK NY 10022
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316

Cantel Medical (Cantel Medical) Headlines